New theranostic platform will combine ultrasensitive detection, high payloads and more efficient cell targeting
CEA-Leti and Akrivis Technologies are to collaborate on the development of an extremely adaptable, efficient and highly targeted drug delivery platform for chemotherapy and other treatments that require a high concentration of powerful drugs to be delivered precisely to targeted cells.
The new platform will be based on Akrivis Technologies’ proprietary Z–TECT technology that targets and detects unusually low levels of proteins and molecular targets and Leti’s Lipidot nanovector delivery capability.
Developed by Akrivis Technologies, a biopharmaceutical company based in Cambridge, Massachusetts, Z–TECT combines nanotechnology, molecular detection and immunology to provide high sensitivity and detection levels across multiple immunoassays and other assay formats, from colorimetric to fluorescent detection in vitro and imaging in vivo.
Developed by Leti and introduced for commercial uses in 2011, the Lipidot technology is a versatile nano-delivery platform based on very small droplets of oil that encapsulate and carry drugs, fluorescent imaging agents or any other lipophilic payload to targeted cells for diagnosis or treatment.
By combining their delivery and targeting platforms, Leti and Akrivis intend to develop a new, more efficient and safer platform to deliver high payloads specifically to targeted cells. The resulting targeted nanoparticles will be optimised in a first phase for research and pre-clinical in vitro and in vivo applications. Then, in a second phase, they will be further developed clinically for in vitro diagnostics, in vivo imaging and targeted therapy.
'The new targeted nanoparticles jointly developed by Leti and Akrivis Technologies will dramatically improve the effectiveness of both diagnosis and treatment of diseases and reduce dangerous or unpleasant side effects,' said Patrick Boisseau, head of Leti’s nanomedicine programme and chairman of the European Technology Platform – Nanomedicine (ETPN). 'While specifically designed to meet the needs of pharmaceutical and biotech companies, the new platform will be customisable for other end-user applications such as diagnostics and theranostics.'
'Detecting disease earlier and delivering the precise drug dosage at the right place at the right moment are major steps towards improving patient diagnosis and treatment as well as controlling healthcare costs,' said Joel Berniac, CEO of Akrivis Technologies. 'Akrivis and Leti have highly complementary nanomed technology platforms that will come together and offer physicians powerful new options for diagnosis diagnosis and treatment.'
Supported by AEPI, the Grenoble-Isère economic development agency, Akrivis Technologies and Leti created a joint lab, which was launched on 2 June.